Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5913441 | Blood Cells, Molecules, and Diseases | 2014 | 5 Pages |
Abstract
We have analyzed some inflammatory biomarkers of macrophage activation and related to the iron profile, including hepcidin and liver iron deposits determined by MRI, in 8 type 1 GD patients with hyperferritinemia. We have explored the changes in this profile after 4 months under therapy with two different iron chelators, deferoxamine or deferasirox, by evaluating response, adverse events and quality of life. We observed a significant reduction in serum ferritin and hepcidin levels and in liver iron deposits. No differences were observed in chitotriosidase activity, CCL18/PARC concentration and IL-4, IL-6, IL-7, IL-10, IL-13, MIP-1α, MIP-1β,TNF-α cytokine levels. After two years on follow-up, clinical and analytical data were improved and stable ferritin levels maintained less than 700 ng/dL.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Biology
Authors
B. Medrano-Engay, P. Irun, J. Gervas-Arruga, M. Andrade-Campos, V. Andreu, P. Alfonso, M. Pocovi, P. Giraldo,